Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBC-102/sebelipase alfa placebo-controlled phase 3 study in lysosomal acid lipase deficiency
2011-002750-31Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2013
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lysosomal acid lipase deficiency (LALD) comparing Sebelipase alfa with Placebo (2 arms). Primary endpoint: ALT normalization at Week 20. Started Jan 2013; status: completed.
02
Drugs
sebelipase alfa
03
Conditions
lysosomal acid lipase deficiency (LALD)
Beyond the preview
Go deeper on 2011-002750-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002750-31.